Loading company…
Cambridge-based Synlogic develops Synthetic Biotics, engineered living-organism therapies for metabolic diseases.
Founded in 2014 in Cambridge, Massachusetts, Synlogic, Inc. develops therapies derived from engineered living organisms, called Synthetic Biotics, for conditions such as phenylketonuria and other metabolic disorders. It works with biopharmaceutical partners and research institutions in North America and Europe. The company has executed 11 deals, and its latest funding was a USD 45.00 mn private placement and follow-on in April 2021, led by CEO Aoife Brennan.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in